Drug-Device Combination Products Market Size, Share, and Industry Analysis, By Product Type (Injectable Drug Delivery Devices, Infusion Pumps, Transdermal Patches, Drug-Eluting Cardiovascular Devices, Orthopedic Drug-Device Combination Products, and Others), By Therapeutic Area (Diabetes, Respiratory Diseases, Oncology, Cardiovascular Diseases, Autoimmune Disorders, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Direct Institutional Sales), and Regional Forecast till 2034

The drug-device combination products market size was valued at USD 155.64 billion in 2025 and is expected to reach a market valuation of USD 167.15 billion in 2026. Furthermore, the market is projected to reach a market valuation of USD 295.87 billion by 2034, exhibiting a CAGR of 7.4% during the forecast period.

The market growth is attributed to the rapid advancements in biologics and advanced devices, which are influencing prominent companies to invest heavily in R&D to develop high-efficacy, premium-priced therapies and next-generation smart devices.

Drug-Device Combination Products Market Driver

Rising Prevalence of Chronic Diseases to Drive the Market Growth

Over the past few years, there has been an increasing prevalence of diabetes, cardiovascular diseases, cancer, and autoimmune disorders, which is driving the demand for long-term pharmacotherapy and implantable or interventional solutions. Such a scenario is expected to drive market expansion in the coming years.

• For instance, according to data published by the International Diabetes Federation, nearly 589.0 million adults aged 20-79 worldwide are currently living with diabetes. Moreover, these cases are expected to reach 853.0 million by 2050.

Download Free sample to learn more about this report.

According to data published by the International Diabetes Federation, the Western Pacific accounted for 215.0 million total cases, the highest among all regions globally, followed by Southeast Asia.

Drug-Device Combination Products Market Restraint

Regulatory Complexity and Approval Delays to Hamper the Market Growth

In several markets, the stringent regulatory requirements across the FDA, EMA, and other authorities extend development timelines and increase compliance costs. For devices, evolving MDR regulations in Europe and cybersecurity compliance requirements globally are creating additional hurdles. Such delays in approvals are expected to limit device adoption and hamper market growth.

• For instance, according to the article published by the National Center for Biotechnology Information (NCBI) in October 2024, the MDR's stricter approval standards and requirements may lead companies to deprioritize the EU market for medical devices.

Drug-Device Combination Products Market Opportunity

Digital Health and Connected Devices to Offer Lucrative Growth Opportunity

The integration of artificial intelligence (AI), smart implants, remote monitoring, and connected diagnostic platforms presents a strong opportunity for differentiation. Smart insulin pens, remote monitoring systems, connected cardiac implants, and AI-powered diagnostic platforms improve outcomes. The merging of pharma and medtech with digital ecosystems enhances patient adherence, offering lucrative opportunities for key players to introduce new products.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence/Incidence of Key Diseases, by Countries/Region, 2025
• Technological Advancements in Drug-Device Combination Products
• Key Industry Developments - (Partnerships, Mergers, and Acquisitions, etc.)
• New Product Launches, by Key Players

Analysis by Product Type

By product type, the market is segmented into Injectable drug delivery devices, infusion pumps, transdermal patches, drug-eluting cardiovascular devices, orthopedic drug-device combination products, and others.

The transdermal patches segment is expected to hold the major share of the global market during the forecast period. The segment’s growth is driven by the launch of transdermal patches for chronic pain and other indications, which is increasing the product's global penetration rate.

• For instance, in February 2025, Aveva Drug Delivery Systems launched all strengths of its generic Fentanyl transdermal patch, a 3-day prescription patch for moderate-to-severe chronic pain in the U.S. market.

Analysis by Therapeutic Area

By therapeutic area, the market is segmented into diabetes, respiratory diseases, oncology, cardiovascular diseases, autoimmune disorders, and others.

The diabetes segment is expected to hold the major share of the global market during the forecast period. The segment’s growth is attributed to the increasing incidence of diabetes globally, which is driving demand for products such as the drug-filled pen injectors, auto-injectors, and others.

• For instance, according to PharmEasy data, by 2050, global diabetes cases are projected to rise by around 73%, with the highest growth expected in Southeast Asia.

Analysis by Distribution Channel

Based on distribution channel, the market is divided into hospital pharmacies, retail pharmacies, online pharmacies, and direct institutional sales.

The retail pharmacies segment is expected to hold the largest share of the global market during the forecast period. The segment’s growth is attributed to the increasing number of retail pharmacies, which offer greater accessibility and discounts, attracting customers to purchase prefilled syringes, injectables, and other drug-device combination products from these channels.

Regional Analysis

Request for Customization   to gain extensive market insights.

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for a 42.4% share of the global drug-device combination products market in 2025. The growth is attributed to a strong network of distribution channels, increased launches of retail and hospital pharmacies, and strong product penetration enabled by prominent players.

• For instance, in February 2024, WinnMed Pharmacy opened a retail pharmacy offering prescription services, OTC meds, vaccines, compounding, and future meds-to-beds for inpatients.

Asia Pacific is expected to grow at the highest CAGR during the forecast period. The region’s growth is attributed to key players' increased focus, driven by a large patient pool and rising awareness of drug-device combination products.

Key Players Covered

The global market for drug-device combination products is highly competitive, with key players launching new products, expanding geographic presence, and more.

The report includes the profiles of the following key players:

• Novo Nordisk A/S (Denmark)
• Eli Lilly and Company (U.S.)
• Sanofi (France)
• AstraZeneca (U.K.)
• Amgen Inc (U.S.)
• Abbott (U.S.)
• Zimmer Biomet (U.S.)
• Stryker (U.S.)
• Novartis AG (Switzerland)
• Medtronic (Ireland)

Key Industry Developments

• September 2025: ApiJect Systems, Corp. submitted a New Drug Application (NDA) to the FDA for approval of its innovative prefilled single-dose plastic syringe containing glycopyrrolate, the world's first injectable medicine using the Blow-Fill-Seal (BFS) technology.
• April 2025: The FDA approved a pre-filled syringe for self-administration of efgartigimod (Vyvgart Hytrulo), an FcRn modulator used in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP).